Skip to Main Content
Skip Navigation Links
 
 

Research & IRB

 


Valley Children’s Hospital participates in a number of clinical trials and research opportunities that benefit both the hospital and our patients.

The Institutional Review Board (IRB) oversees all research and educates hospital staff on the different research processes at the hospital. Research conducted at Children's must be:

  • scientifically valid,
  • conducted in such a way as to respect the rights and welfare of our patients, and
  • in compliance with all applicable federal and institutional regulations and policies. 

Composed of doctors, nurses, community members and hospital staff,  the IRB brings together a wide variety of experience.

Types of research include:

  • Clinical Trials – Sponsored either by a private corporation or the National Institutes of Health, these trials provide practical investigation into a drug or medical device, to be used for future marketing applications.
  • Registries – Children’s participates in a number of nationwide registries that capture data on specific populations for use in research of chronic pediatric conditions.  We contribute data to registries on hematology, cystic fibrosis, and diabetes.
  • Oncology ResearchThe Craycroft Cancer Center at Children’s Hospital is part of the Children’s Oncology Group, participating in more than 100 ongoing clinical trials.
  • Investigator Sponsored Research – The largest area of research at Children’s, these projects involve retrospective chart review.  Researchers look at data that has been collected to find trends in patient treatment and outcome, as well as answer questions that arise during research.

For more information, please contact research@valleychildrens.org or IRB@valleychildrens.org.

Current Clinical Trials as of September 1, 2015 

Cardiology

  • Use of the Contegra Pulmonary Valve Conduit in Appropriate Patients at Children's Hospital Central California
    Physician investigator:  Edwin Petrossian, MD
  • Closure of Muscular Ventricular Septal Defects with the AMPLATZER (Muscular VSD Occluder) Post Approval Study (Muscular VPA Study)
    Physician investigator: Carl Owada, MD
  • Compassionate Use of the CP Covered Stent for treatment of Aortic Arch Abnormalities
    Physician investigator: Carl Owada, MD
  • Comparison Between Surgical versus Balloon Angioplasty versus Intravascular Stent Placement for Recurrent Native Coarctation of the Aorta
    Physician investigator: Carl Owada, MD
  • Neurodevelopment Outcomes in Pediatric Patients < 10 years of age with Open Heart Surgery for Repair of Isolated VSD
    Physician investigator: Paul Francis, MD
  • Request for Emergency Use of St. Jude 15mm Aortic Valve
    Physician investigator: Malcom J. MacDonald, MD
  • Outcomes after Surgical Management of Patients with Congenital Heart Defects
    Physician investigator: Edwin Petrossian, MD

Endocrinology

  • The ANSWER Program® - American Norditropin® Stuides: Web Enabled Research. An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
    Physician investigator: Swati Banerjee, MD
  • TrialNet Natural History Study of the Development of Type I Diabetes
    Physician investigator: Swati Banerjee, MD
  • A multicenter, observation study of pediatric female patients with central precocious puberty receiving Supprelin LA® (histrelin acetate), a hydrogel subcutaneous implant
    Physician investigator: Nedim Cakan, MD
  • TODAY Study Group Genetics Protocol
    Physician investigator: Swati Banerjee, MD

Gastroenterology

  • The Pediatric ERCP Databse Initiative (PEDI)
    Physician investigator: Roberto Gugig, MD
  • Epidemiological and Clinical Characteristics of Children with Newly Diagnosed IBD in the Central Valley, CA
    Physician investigator: Clifton Huang, MD

Genetics

  • Compassionate Use for Lysosomal Acid Lipase (LALD)
    Physician investigator: Joseph Shen MD, PhD
  • Medical Home for Children with Down Syndrome
    Physician investigator: Joseph Shen, MD, PhD

Hematology

  • Data collection on complications of Hemophilia and serum testing and storage
    Physician investigator: Vinod Balasa, MD
  • Quality of Life in Pediatric Palliative Care Patients
    Physician investigator: Daniel Ozeran, MD
  • American Thrombosis and Hemostasis Network-ATHN Dataset
    Physician investigator: Vinod Balasa, MD

Hospital

  • Evaluation of a modified Pediatric Early Warning System with the use of electronic nursing documentation in Children’s Hospital Central California
    Physician investigator: Jolie Limon, MD

Infectious Disease

  • Coccidioidomycosis in Children: A Retrospective Case Series
    Physician investigator: Mary-Anne Tablizo, MD
  • Inflammatory Cytokines and Adaptive Immune Response as Biomarkers of Coccidiodomycosis
    Physician investigator: Fouzia Naeem, MD
  • Temocillin Single Patient IND - Emergency Use
    Physician Investigator: Fouzia Naeem, MD
  • Psychosocial Factors affecting Coccidiodomycosis Patients
    Physician investigator: Fouzia Naeem, MD

Neonatal Intensive Care Unit

  • Oscillatory versus Non-Oscillatory Nasal Continuous Airway Pressure for Neonatal Respiratory Support
    Physician investigator: Jeffrey Pietz, MD

Neurosurgery

  • X-Ray Verified Accuracy of the Aesculap-Miethke proGAV® Adjustable Shunt Pressure Setting Verification Instrument
    Physician investigator: Gary Magram, MD
  • Neurosurgery Tissue Bank
    Physician investigator: Patricia Clerkin, MD

Nursing

  • HEADS UP Program Questionnaire
    Principal investigator: Mary Quintero, RN
  • Pediatric Early Warning System (PEWS) Score Tool Pilot Study
    Principal investigator: Mary-Ann Robson, RN
  • Development and testing of an instrument to measure Nursing Perception of Components of Professional Practice
    Principal investigator: Denise Vermeltfoort, RN
  • Retrospective Case Review Pre-Post PICU Patient Centered Sedation Guideline Implementation
    Principal Investigator: Carole Cooper, MHA, MSN, RN, ACCNS-P
  • Evaluating the Effectiveness of an Evidence-Based Gastrointestinal Curriculum in Pediatric Registered Nurses
    Investigator: Sandra Huizar, RN

Oncology

  • A Multi-Center, Open Label, Non-Controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients with Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or with Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to either Imatinib or Dasatinib
    Physician investigator: Daniel Ozeran, MD
  • A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pedicatric Patients with Mewly Diagnosed Philadelphia Chormosome Positive Acute Lymphoblastic Leukemia
    Physician investigator: Daniel Ozeran, MD
  • A Phase 1 Dose Finding Study Of Panobinostat in Children With Refractory Hematologic Malignancies
    Physician investigator: Wendy Cheng, MD
  • National Wilms Tumor Late Effects Study
    Physician investigator: Vonda Crouse, MD
  • Northern California Childhood Leukemia (UCB) (Molecular Epidemiology of Childhood Leukemia & Environmental Exposures)
    Physician investigator: Vonda Crouse, MD
  • Late Effects/Survivorship Program
    Physician investigator: John Gates, MD
  • Iron Overload in Patients with Childhood Cancer
    Physician investigator: Daniel Ozeran, MD
  • Age, obesity, ethnicity, treatment type, type of malignancy diagnosis and history of other diseases play a role in being 25-OH Vit D def in childhood cancer survivors in the Central Valley of California
    Physician investigator: John Gates, MD
  • RadART-Pro: A prospective multi-institutional study to assess the risk of radiation induced vasculopathy and stroke as well as stroke recurrence in children with cancer who received radiation therapy to the neck and/or brain
    Physician investigator: David Samuel, MD
  • AALL02P2, Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>/=18 months)
    Physician investigator: Vonda Crouse, MD
  • AALL0331,Standard Risk B-precursor Acute Lymphoblastic Leukemia
    Physician investigator: Vonda Crouse, MD
  • ANBL0032,Phase III Randomized Study of Chimeric Anti-GD1 in High Risk Neuroblastoma Following Myeloablative therapy and Autologous Stem Cell Rescue
    Physician investigator: Vonda Crouse, MD
  • AALL0433,Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
    Physician investigator: Vonda Crouse, MD
  • AALL0434,Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
    Physician investigator: Vonda Crouse, MD
  • AALL05B1,A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
    Physician investigator: Vonda Crouse, MD
  • AALL0631,A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431, NSC#617807)
    Physician investigator: Vonda Crouse, MD
  • AALL08B1,Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
    Physician investigator: Vonda Crouse, MD
  • AALL0932,Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
    Physician investigator: Vonda Crouse, MD
  • AALL1131,A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
    Physician investigator: Vonda Crouse, MD
  • AALL1231,A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
    Physician investigator: Vonda Crouse, MD
  • AAML0631,Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during Consolidation
    Physician investigator: Vonda Crouse, MD
  • AAML08B1,Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
    Physician investigator: Vonda Crouse, MD
  • AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
    Physician investigator: Vonda Crouse, MD
  • ACCL0933, A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
    Physician investigator: Vonda Crouse, MD
  • ACCRN07,Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
    Physician investigator: Vonda Crouse, MD
  • ACNS0332,Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
    Physician investigator: Vonda Crouse, MD
  • ACNS0334,A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate
    Physician investigator: Vonda Crouse, MD
  • ACNS0821,Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
    Physician investigator: Vonda Crouse, MD
  • ACNS0822,A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma
    Physician investigator: Vonda Crouse, MD
  • ACNS0831,Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
    Physician investigator: Vonda Crouse, MD
  • ACNS0927,A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation,Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
    Physician investigator: Vonda Crouse, MD
  • ACNS1022,A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
    Physician investigator: Vonda Crouse, MD
  • AEWS07B1,A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
    Physician investigator: Vonda Crouse, MD
  • AEWS1031,A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
    Physician investigator: Vonda Crouse, MD
  • AHEP0731, Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment
    Physician investigator: Vonda Crouse, MD
  • AHOD04B1,Hodgkin Disease Banking Study
    Physician investigator: Vonda Crouse, MD
  • AHOD0831,A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma
    Physician investigator: Vonda Crouse, MD
  • ALTE05N1,Umbrella Long-term Follow-up Protocol
    Physician investigator: Vonda Crouse, MD
  • ALTE07C1,Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
    Physician investigator: Vonda Crouse, MD
  • ALTE11C2, Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
    Physician investigator: Vonda Crouse, MD
  • ANBL00B1,Neuroblastoma Classification Biology Studies
    Physician investigator: Vonda Crouse, MD
  • ANBL00P3,A Phase III randomized trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone
    Physician investigator: Vonda Crouse, MD
  • ANBL0532,Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma
    Physician investigator: Vonda Crouse, MD
  • ANBL1221,A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
    Physician investigator: Vonda Crouse, MD
  • ANBL1232,Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
    Physician investigator: Vonda Crouse, MD
  • ANHL12P1,A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117
    Physician investigator: Vonda Crouse, MD
  • AOST0331,A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy
    Physician investigator: Vonda Crouse, MD
  • AOST06B1,AOST1322,A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
    Physician investigator: Vonda Crouse, MD
  • ARAR0331,Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
    Physician investigator: Vonda Crouse, MD
  • AREN0321,Treatment of High Risk Renal Tumors
    Physician investigator: Vonda Crouse, MD
  • AREN03B2,Renal Tumors Classification, Biology, and Banking Study
    Physician investigator: Vonda Crouse, MD
  • AREN0532,Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
    Physician investigator: Vonda Crouse, MD
  • AREN0533,Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
    Physician investigator: Vonda Crouse, MD
  • AREN0534,Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
    Physician investigator: Vonda Crouse, MD
  • ARST0332,Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Patients Under 30 Years of Age
    Physician investigator: Vonda Crouse, MD
  • ARST0531,Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
    Physician investigator: Vonda Crouse, MD
  • ARST08P1,A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
    Physician investigator: Vonda Crouse, MD
  • ARST0921,A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
    Physician investigator: Vonda Crouse, MD
  • D9902,A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
    Physician investigator: Vonda Crouse, MD
  • AALL1122,A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66,971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL).  AKA: BMS ID CA180-372
    Physician investigator: Vonda Crouse, MD
  • ABTR01B1,COG Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
    Physician investigator: Vonda Crouse, MD
  • AALL0232,High Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
    Physician investigator: Vonda Crouse, MD
  • ACNS02B3,COG Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
    Physician investigator: Vonda Crouse, MD
  • ACNS0331,Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: Phase III Double Randomized Trial
    Physician investigator: Vonda Crouse, MD
  • ARST1321,A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND#118613)
    Physician investigator: Vonda Crouse, MD
  • AEWS1221,Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma: An intergroup NCTN Phase II Study
    Physician investigator: Vonda Crouse, MD
  • AEWS0031,Trial of Chemotherapy intestification through interval compression in Ewings Sarcoma related tumors
    Physician investigator: Vonda Crouse, MD
  • ACNS1221,A Phase II study for the treatment of Non-Metastatic Nodular desmoplastic Medulloblastoma in children less than 4 years of age
    Physician investigator: Vonda Crouse, MD
  • AHOD1331,A Randomized Phase III study of Brentuximab Vedotin (SGN-35, IND#117117) for newly diagnosed high risk classical hodgkin lymphoma (chL) in children and adolescents
    Physician investigator: Vonda Crouse, MD
  • AAML0531,A Phase III Randomized Trial of Gemtuzumab Ozogamicin (mylotarg) combined with conventional chemotherapy for De Novo Acute Myeloid Leukemia (AML) in children, adolescents, and young adults
    Physician investigator: Vonda Crouse, MD
  • AAML0431, The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years: A Groupwide Phase III Study
    Physician investigator: Vonda Crouse, MD
  • AALL03B1, Classification of Acute Lymphoblastic Leukemia
    Physician investigator: Vonda Crouse, MD
  • Clinical Outcomes of Pediatric Primitive Neuroectodermal Tumors and medulloblastomas with correlation of molecular, radiologic, and treatment-associated parameters
    Physician investigator: David Samuel, MD
  • The use of postcard reminders and its impact on successful weight management and improvement of exercise, diet, and motivation and interest in weight loss in overweight childhood cancer survivors
    Physician investigator: John Gates, MD
  • Echocardiographic Measurements in Childhood Cancer Survivors
    Physician investigator: John Gates, MD
  • P9645,Phase III Protocol for Treatment of Children with Hepatoblastoma
    Physician investigator: Vonda Crouse, MD
  • ARST0331,Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide with or without Radiation Therapy for Patients with newly Diagnosed Low Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
    Physician investigator: Vonda Crouse, MD
  • AHOD1221,A Phase ½ Study of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
    Physician investigator: Vonda Crouse, MD
  • AHOD0431,Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease
    Physician investigator: Vonda Crouse, MD
  • AHOD0031,Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
    Physician investigator: Vonda Crouse, MD
  • AGCT0132,Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors
    Physician investigator: Vonda Crouse, MD
  • AEWS02B1,Groupwide Biology and Banking Study for Ewing Sarcoma
    Physician investigator: Vonda Crouse, MD
  • ADVL1121,A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND#69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
    Physician investigator: Vonda Crouse, MD
  • ACNS0122,Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery to Eliminate All Measurable Disease Prior to Radiotherapy for NGGCT
    Physician investigator: Vonda Crouse, MD
  • ACNS0121,Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletetly Resected Ependymoma and Observations for Completely Resected, Differentiated, Supratentorial Ependymoma
    Physician investigator: Vonda Crouse, MD
  • A3973, Randomized Study of Purged vs. Unpurged PBSC Transplant Following Dose Intensive Induction Therapy for High Risk NBL
    Physician investigator: Vonda Crouse, MD
  • 1991, Escalating Dose Intravenous Methotrexate without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Chidlren with Standard Risk Acute Lymphoblastic Leukemia
    Physician investigator: Vonda Crouse, MD
  • AALL0031, A Children’s Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (STI-571) (GLEEVEC)
    Physician investigator: Vonda Crouse, MD
  • AAML1331, A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study
    Physician investigator: Vonda Crouse, MD
  • AALL1421, A Dose Confirmation and Pharmacokinetic Study of Pegrisantaspase Administered as Intravenous (IV) Infusion in children and Young Adults with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Pegaspargase (Oncaspar)
    Physician investigator: Daniel Ozeran, MD
  • AALL07P1, A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND#58, 442) in combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
    Physician investigator: Vonda Crouse, MD
  • The International Pleuropulmonary Blastoma (PPB) Registry
    Physician investigator: Vonda Crouse, MD

Orthopaedics

  • Bracing in Adolescent Idiopathic Scoliosis II (BrAIST II): Minimum 2- Year Follow-Up of BrAIST Cohort
    Physician investigator: Joseph Gerardi, DO
  • Verticle Expandable Prosthetic Titanium Rib (VEPTR)
    Physician investigator: Michael Elliott, MD
  • Flexible Intramedullary Fixation of Pediatric Femur Fractures with a Single Lateral Incision
    Physician investigator: Joseph Gerardi, DO
  • Psychosocial Preparation Prior to Spine Surgery
    Principal investigator: Mary Beth Jones, M. Ed. CCLS
  • Perioperative Outcomes of Multilevel Posterior Spinal Fusion in Adolescent Scoliosis with Two Energy Dissection Techniques
    Physician investigator: Michael Elliott, MD
  • Retrospective Review of Pediatric Elbow Fractures
    Physician investigator: Michael Elliott, MD
  • The Chest Wall and Spine Deformity Registry
    Physician investigator: Michael Elliott, MD

Pediatric Intensive Care Unit

  • Epidemiology of Life-threatening Bordatella Pertussis in Young Infants
    Physician investigator: Ana Lia Graciano, MD
  • Development of a Pediatric Sepsis Tool
    Physician investigator: Ana Lia Graciano, MD
  • Pediatric Surgery

    • Hirschsprung Disease Research Collaboration
      Physician investigator: Doug Tamura, MD

    Pharmacy

    • The Impact of Text Message Reminders on INR Lab Appointment Adherence in an Ambulatory Pharmacy Managed Pediatric Warfarin Clinic
      Investigator: Cheryl Imoto, PharmD & Joanna Cheung, PharmD
    • Adherence to Clinical Practice Guidelines in the Treatment of Hospitalized Children with Uncomplicated Community Acquired Pneumonia
      Investigator: Brenik Kuzmic, PharmD & Megan Ikeda, PharmD
    • Dexamethasone versus Prednisone for the Inpatient Treatment of Pediatric Acute Asthma Exacerbations
      Investigator: Nicole Dinh, PharmD & Nicole Rivera, PharmD
    • Evaluation of Fluconazole Prophylaxis for Prevention of Invasive Candida Infections in Preterm Neonates
      Investigator: Rosanna Tran, PharmD & Brenik Kuzmic, PharmD
    • Evaluation of medication reconciliation upon admission to a children’s hospital
      Investigator: Lynn Warner, PharmD

    Plastics

    • Molecular Genetic Analysis of Limb Malformations
      Physician investigator: Peter Witt, MD

    Pulmonology

    • A phase 3, rollover study to evaluate the safety and efficacy of long-term treatment with lumacaftor in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation
      Physician investigator: Reddivalam Sudhakar, MD
    • Cystic Fibrosis Patient Registry
      Physician investigator: Reddivalam Sudhakar, MD
    • Comparison of Invasive versus Non-Invasive Mechanical Ventilation in Pediatric Restrictive Lung Disease
      Physician investigator: Mary-Anne Tablizo, MD
    • Review of Pediatric Primary Pulmonary Coccidioidomycosis
      Physician investigator: John Moua, MD
    • Collection of CFTR Mutations for Laboratory Quality Assurance
      Physician investigator: Reddivalam Sudhakar, MD
    • Retrospective Review of Dexamethasone versus Prednisone Use in the Inpatient Management of Acute Asthma Exacerbation
      Physician investigator: John Moua, MD
    • Identification and Characterization of CFTR Mutations Among Nonwhite Patients with Cystic Fibrosis to Improve the Clinical Sensitivity of Neonatal Screening and Diagnostic Testing
      Physician investigator: Reddivalam Sudhakar, MD

    Rheumatology

    • Latino Narrative Medicine in Patients with Juvenile Onset Systemic Lupus Erythematosus
      Physician investigator: Edsel Arce-Hernandez, MD

    Urology

    • A Retrospective Study Comparing Bowel Regimen versus Anticholinergic Therapy in Resolving Daytime Incontinence and Lower Urinary Tract Dysfunction
      Physician investigator: Tracy Chin, NP

     

    Additional information is available on significant conflicts of interest (COI) regarding PHS funded studies.